| Name | Title | Contact Details |
|---|
Alliance Physical Therapy Partners is the 7th largest physical therapy provider in the U.S., with more than 70 outpatient PT locations nationwide. The company was founded by patient-focused healthcare experts who were seeking to transform the traditional healthcare experience by infusing innovation and passion so that more people can enjoy the benefits of physical therapy. Alliance Physical Therapy Partners is also the parent company of Work-Fit, an injury prevention solutions provider who applies sports medicine techniques in the workplace to prevent injuries. In addition, BioCorrect Custom Orthotics Lab is part of the Alliance Physical Therapy Partner brands, providing a patented foot alignment system, evaluation process, and innovative custom and semi-custom foot orthotics for competitive athletics, outdoor recreation or people just living life to the fullest. Alliance Physical Therapy Partners is an affiliate of GPB Capital Holdings, LLC focused on acquiring private physical therapy practices across the U.S. to provide practice owners the opportunity to expand their footprint while receiving operational guidance and financial support. The Alliance team includes former private practice owners, direct marketing professionals and operations experts who have experience running and growing successful healthcare organizations. About GPB Capital Holdings, LLC GPB Capital is a New York-based alternative asset management firm focusing on acquiring income-producing private companies. GPB Capital seeks to provide its portfolio companies with the strategic planning, managerial insight, and capital needed to enable strong businesses to achieve the next level of growth and profitability. GPB Capital has over $1.5 billion in assets under management[i] and has acquired or invested in more than 160 portfolio companies. For more information, please visit www.gpb-cap.com. [i] Which is different and distinct from GPB Capital`s “Regulatory AUM.”
Founded in 2017, Sift Healthcare is a Milwaukee-based healthcare payments analytics and data science company. Sift`s Payments Intelligence Platform, machine learning integrations and Rev/Track Insights Suite enable healthcare providers and payers to fully leverage their payments data to accelerate insurance reimbursement, improve patient payment strategies and optimize revenue cycle efficiency.
OPMEDIC Group Inc. is a Outremont, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TestZone is a global health security provider of multi-layered screening programs to keep spaces safer. Founded by internationally recognized experts in medical diagnostics and public health, we create customizable, on-site solutions for any institution or business that needs to keep its doors open by keeping its people healthy amid always evolving health threats.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.